| 90.8 -15.37 (-14.48%) | 05-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 117.05 |
1-year : | 129.98 |
| Resists | First : | 100.21 |
Second : | 111.29 |
| Pivot price | 102.72 |
|||
| Supports | First : | 82.3 |
Second : | 68.47 |
| MAs | MA(5) : | 103.74 |
MA(20) : | 102.33 |
| MA(100) : | 91.46  |
MA(250) : | 82.98 |
|
| MACD | MACD : | 1.1 |
Signal : | 2 |
| %K %D | K(14,3) : | 60.2 |
D(3) : | 73.6 |
| RSI | RSI(14): 38.2 |
|||
| 52-week | High : | 111.29 | Low : | 55.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MLAB ] has closed below the lower bollinger band by 14.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ MLAB ] is to continue within current trading range. Bollinger Bands are 18.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 105.43 - 106.07 | 106.07 - 106.54 |
| Low: | 81.09 - 81.76 | 81.76 - 82.26 |
| Close: | 89.83 - 90.92 | 90.92 - 91.73 |
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Wed, 27 May 2026
Mesa Labs 4Q Loss/Shr 75c >MLAB - Moomoo
Wed, 27 May 2026
Is Mesa Laboratories (MLAB) Modestly Undervalued Despite Q4 FY26 - GuruFocus
Wed, 27 May 2026
MESA LABORATORIES ($MLAB) Releases Q4 2026 Earnings - Quiver Quantitative
Wed, 27 May 2026
Mesa Labs: Fiscal Q4 Earnings Snapshot - WKYC
Wed, 27 May 2026
MLAB: FY26 revenue rose 3.4% to $249.1M, with strong margins and improved profitability - TradingView
Wed, 27 May 2026
Mesa Laboratories reports FY26 revenue $249.1M, operating income $18.5M, AOI ex-unusual $63.5M - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Technology
|
|
|
Industry:
Hardware, Equipment & Parts
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 94.1 (%) |
| Shares Short | 199 (K) |
| Shares Short P.Month | 221 (K) |
| EPS | 0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.79 |
| Profit Margin | 1.5 % |
| Operating Margin | 12.2 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | 2.1 % |
| Qtrly Rev. Growth | 3.5 % |
| Gross Profit (p.s.) | 27.98 |
| Sales Per Share | 44.84 |
| EBITDA (p.s.) | 7.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 42 (M) |
| Levered Free Cash Flow | 37 (M) |
| PE Ratio | 139.69 |
| PEG Ratio | 0 |
| Price to Book value | 2.68 |
| Price to Sales | 2.02 |
| Price to Cash Flow | 12.06 |
| Dividend | 0.15 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|